NFKB1 and lung carcinoma: Synergistic inhibition of lung cancer cells by EGCG with other drugs has also been reported, such as leptomycin B (Cromie and Gao, 2015), NF-κB inhibitor BAY11-7082 (Zhang et al., 2019), gefitinib (Meng et al., 2019), and cisplatin (Jiang et al., 2016).